164 related articles for article (PubMed ID: 34776047)
21. Targeted and Systematic Biopsy for the Diagnosis and Management of Prostate Cancer - A Case for Lesion Targeted-Only Biopsies.
Tam JO; Ahmed HU
Clin Oncol (R Coll Radiol); 2020 Mar; 32(3):136-143. PubMed ID: 32035580
[TBL] [Abstract][Full Text] [Related]
22. MR Imaging-Guided Focal Treatment of Prostate Cancer: An Update.
Nour SG
Radiol Clin North Am; 2018 Mar; 56(2):301-318. PubMed ID: 29420984
[TBL] [Abstract][Full Text] [Related]
23. Multiparametric magnetic resonance imaging in the detection of prostate cancer.
Durmus T; Baur A; Hamm B
Aktuelle Urol; 2014 Mar; 45(2):119-26. PubMed ID: 24700068
[TBL] [Abstract][Full Text] [Related]
24. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance.
Natarajan S; Jones TA; Priester AM; Geoghegan R; Lieu P; Delfin M; Felker E; Margolis DJA; Sisk A; Pantuck A; Grundfest W; Marks LS
J Urol; 2017 Oct; 198(4):839-847. PubMed ID: 28396184
[TBL] [Abstract][Full Text] [Related]
25. Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy.
Lu AJ; Syed JS; Ghabili K; Hsiang WR; Nguyen KA; Leapman MS; Sprenkle PC
Eur Urol; 2019 Jul; 76(1):14-17. PubMed ID: 31047733
[TBL] [Abstract][Full Text] [Related]
26. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging-transrectal ultrasound image fusion guidance of prostate biopsies: current status, challenges and future perspectives.
Boesen L
Scand J Urol; 2019; 53(2-3):89-96. PubMed ID: 31006323
[TBL] [Abstract][Full Text] [Related]
28. Focal Therapy for Prostate Cancer: Pending Questions.
Cathelineau X; Sanchez-Salas R
Curr Urol Rep; 2016 Dec; 17(12):86. PubMed ID: 27761805
[TBL] [Abstract][Full Text] [Related]
29. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
30. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
[TBL] [Abstract][Full Text] [Related]
31. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
[TBL] [Abstract][Full Text] [Related]
32. Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.
Borges RC; Tourinho-Barbosa RR; Glina S; Macek P; Mombet A; Sanchez-Salas R; Cathelineau X
J Urol; 2021 Jan; 205(1):129-136. PubMed ID: 33119421
[TBL] [Abstract][Full Text] [Related]
33. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study.
Rastinehad AR; Anastos H; Wajswol E; Winoker JS; Sfakianos JP; Doppalapudi SK; Carrick MR; Knauer CJ; Taouli B; Lewis SC; Tewari AK; Schwartz JA; Canfield SE; George AK; West JL; Halas NJ
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18590-18596. PubMed ID: 31451630
[TBL] [Abstract][Full Text] [Related]
34. Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies.
Covin B; Roumiguié M; Quintyn-Ranty ML; Graff P; Khalifa J; Aziza R; Ploussard G; Portalez D; Malavaud B
World J Urol; 2019 Feb; 37(2):269-275. PubMed ID: 30145777
[TBL] [Abstract][Full Text] [Related]
35. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
Lebastchi AH; George AK; Polascik TJ; Coleman J; de la Rosette J; Turkbey B; Wood BJ; Gorin MA; Sidana A; Ghai S; Tay KJ; Ward JF; Sanchez-Salas R; Muller BG; Malavaud B; Mozer P; Crouzet S; Choyke PL; Ukimura O; Rastinehad AR; Pinto PA
Eur Urol; 2020 Sep; 78(3):371-378. PubMed ID: 32532513
[TBL] [Abstract][Full Text] [Related]
36. Novel focal therapy treatment options for prostate cancer.
Werntz RP; Eggener SE
Curr Opin Urol; 2018 Mar; 28(2):178-183. PubMed ID: 29232270
[TBL] [Abstract][Full Text] [Related]
37. [Focal therapy for prostate cancer].
Schostak M
Urologe A; 2019 May; 58(5):518-523. PubMed ID: 30734839
[TBL] [Abstract][Full Text] [Related]
38. Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy.
Matsuoka Y; Numao N; Saito K; Tanaka H; Kumagai J; Yoshida S; Ishioka J; Koga F; Masuda H; Kawakami S; Fujii Y; Kihara K
BJU Int; 2016 Jan; 117(1):94-101. PubMed ID: 25124332
[TBL] [Abstract][Full Text] [Related]
39. Robotic prostate biopsy and its relevance to focal therapy of prostate cancer.
Ho H; Yuen JS; Cheng CW
Nat Rev Urol; 2011 Sep; 8(10):579-85. PubMed ID: 21931344
[TBL] [Abstract][Full Text] [Related]
40. Prostate focal therapy: the rule or exception?
Tay KJ
Curr Opin Urol; 2018 Nov; 28(6):512-521. PubMed ID: 30124517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
